Physician profile
Peter A Lipson
NPI 1396729737
$4,966.30
in general payments reported to CMS, 2019-2025
25 companies · $1,050 in 2025
The $1,050 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $324 · 2021: $627 · 2022: $1,002 · 2023: $869 · 2024: $796 · 2025: $1,050.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,714.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,094.08 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $595.93 | 2019-2025 | |
| Abbvie INC. | $478.19 | 2021-2025 | |
| Amgen INC. | $451.64 | 2019-2024 | Prolia, Evenity, Repatha |
| Lilly USA, LLC | $378.78 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $321.70 | 2019-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $275.16 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $233.30 | 2021-2022 | |
| Exact Sciences Corporation | $202.38 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $177.40 | 2019-2023 | |
| Xeris Pharmaceuticals, INC. | $121.87 | 2022-2023 | Gvoke Hypopen |
| Dexcom, INC. | $99.30 | 2022-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $76.68 | 2020-2025 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $73.69 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.63 | 2020-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $63.84 | 2021-2025 | Capvaxive, Gardasil 9 |
| Astellas Pharma US INC | $58.52 | 2021-2024 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $37.10 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $31.67 | 2024-2025 | Opsumit, Uptravi |
| Phathom Pharmaceuticals, INC. | $31.34 | 2024 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $24.80 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $19.28 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $17.65 | 2021 | |
| Amarin Pharma, INC. | $17.23 | 2021 | |
| Horizon Therapeutics Plc | $17.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Lipson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.